Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Add as a preferred source on Google
LAKE FOREST, Ill., May 07, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference in a session scheduled for 1:30 pm ET on Tuesday, May 22, 2018 in New York, NY.
This presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
John B. Thomas
SVP, Investor Relations and Corporate Communications
[email protected]
